Cartalax
20 mg (lyophilized)
CAS #:
85806-95-7
LOT #:
261005
Purity:
99.84%
Endotoxin:
PASS
Cap colour is for illustration purposes only
Cartalax
20 mg (lyophilized)
+ $25 flat-rate shipping · free at $300+ · Interac e-Transfer ·
Volume pricing
Orders with confirmed payment before 2 PM EST on business days ship same day
About this compound
Cartalax (Ala-Glu-Asp-Leu) is a synthetic tetrapeptide bioregulator originally derived from cartilage tissue extracts. It belongs to a class of short peptide bioregulators developed in Russian biogerontology research, where it has been studied for its potential role in modulating gene expression in chondrocytes and supporting the structural integrity of cartilage and connective tissue. Preclinical research has examined Cartalax for its proposed cytoprotective and regenerative properties in articular cartilage models, particularly in the context of age-related cartilage degradation, oxidative stress, and inflammatory conditions affecting joint tissue. As a bioregulator peptide, it is proposed to interact with gene promoter regions and influence protein synthesis patterns in cartilage-forming cells.
Key chemical details
- Formula weight
- 446.45 g/mol
- Molecular formula
- C18H30N4O9
- Common synonyms
- AEDL, Ala-Glu-Asp-Leu
Storage and handling
Store at -20°C lyophilized, away from moisture and UV light. Keep vials sealed until use. Stable for 2+ years in a non-frost-free freezer.
Preclinical research references
Provided for informational context only. All cited studies involve preclinical or in vitro models. Results do not predict human safety or efficacy. These references do not constitute medical claims.
- In vitro studies using isolated chondrocyte cultures demonstrated that Cartalax treatment reduced markers of oxidative stress and attenuated pro-inflammatory cytokine-induced apoptotic signaling, suggesting potential cytoprotective activity in articular cartilage cells (Khavinson et al., 2002)
- Aged rodent models showed that Cartalax administration was associated with partial preservation of cartilage matrix integrity, reduced proteoglycan loss, and decreased expression of matrix metalloproteinases (MMPs) involved in cartilage degradation compared to untreated aged controls (Malinin et al., 2007)
- Peptide bioregulator studies indicated Cartalax may influence chromatin conformation and gene expression patterns in chondrocyte nuclei, with observed modulation of collagen type II and aggrecan synthesis markers in ex vivo cartilage tissue preparations (Khavinson & Morozov, 2003)
Shipping & returns
1–5 business days (5–7 for BC, NL and remote areas), Canada-wide tracked courier, double tamper-proof packaging.
All sales final. Damaged or incorrect orders must be reported within 24 hours with photos.
Every batch independently tested for purity. COA on file and available before purchase.
FAQ — Cartalax
For research use only. Not for human or veterinary administration.